IN2012DN00303A - - Google Patents

Info

Publication number
IN2012DN00303A
IN2012DN00303A IN303DEN2012A IN2012DN00303A IN 2012DN00303 A IN2012DN00303 A IN 2012DN00303A IN 303DEN2012 A IN303DEN2012 A IN 303DEN2012A IN 2012DN00303 A IN2012DN00303 A IN 2012DN00303A
Authority
IN
India
Prior art keywords
avß5
integrin
treating
preventing
sepsis
Prior art date
Application number
Inventor
Dean Sheppard
George Su
Amba Atakilit
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IN2012DN00303A publication Critical patent/IN2012DN00303A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides compositions and methods for treating and preventing disease associated with avß5 integrin by blocking binding to avß5 integrin. In particular, antibodies specific for avß5 integrin are useful for preventing, treating, and reversing sepsis.
IN303DEN2012 2009-07-24 2010-07-26 IN2012DN00303A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22841609P 2009-07-24 2009-07-24
PCT/US2010/043211 WO2011011775A1 (en) 2009-07-24 2010-07-26 Methods and compositions for treating and preventing disease associated with avb5 integrin

Publications (1)

Publication Number Publication Date
IN2012DN00303A true IN2012DN00303A (en) 2015-05-08

Family

ID=43499449

Family Applications (1)

Application Number Title Priority Date Filing Date
IN303DEN2012 IN2012DN00303A (en) 2009-07-24 2010-07-26

Country Status (11)

Country Link
US (1) US10087252B2 (en)
EP (1) EP2456460A4 (en)
JP (1) JP5755647B2 (en)
KR (1) KR101752515B1 (en)
CN (1) CN102481347A (en)
AU (1) AU2010275367B2 (en)
BR (1) BR112012001463A2 (en)
CA (1) CA2767409C (en)
IL (1) IL217406A (en)
IN (1) IN2012DN00303A (en)
WO (1) WO2011011775A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201215414D0 (en) * 2012-08-30 2012-10-17 Isis Innovation Composition and use
JP2016515120A (en) * 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Treatment and prevention of acute kidney injury using anti-alpha Vbeta5 antibody
EP3191519A1 (en) * 2014-09-12 2017-07-19 Biogen MA Inc. Humanized anti-alpha v beta 5 antibodies and uses thereof
US11192889B2 (en) 2016-07-05 2021-12-07 The Rockefeller University Tetrahydronaphthyridinepentanamide integrin antagonists
KR20220005471A (en) * 2019-04-08 2022-01-13 바이오젠 엠에이 인코포레이티드 Anti-integrin antibodies and uses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
DE3689123T2 (en) 1985-11-01 1994-03-03 Xoma Corp MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5527679A (en) 1991-05-01 1996-06-18 Dana Farber Cancer Institute β5 protein and DNA encoding the same
DE4142366A1 (en) 1991-07-15 1993-06-24 Thomae Gmbh Dr K PHENYLALKYL DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
DE4123341A1 (en) 1991-07-15 1993-01-21 Thomae Gmbh Dr K PHENYL ALKYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6291196B1 (en) 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US7053041B1 (en) 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
UA60311C2 (en) 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Vitronectin receptor antagonists
CO4920232A1 (en) 1997-01-08 2000-05-29 Smithkline Beecham Corp DIBENZO [A, D] CYCLLOHEPTANE ACETIC ACIDS WITH VITRONECTIN RECEPTOR ANTAGONIST ACTIVITY
AR013269A1 (en) 1997-08-04 2000-12-13 Scras PRODUCT CONTAINING AT LEAST A DOUBLE FILAMENT RNA COMBINED WITH AT LEAST AN ANTI-VIRAL AGENT, FOR THERAPEUTIC USE IN THE TREATMENT OF A VIRAL DISEASE, ESPECIALLY OF VIRAL HEPATITIS
ATE511850T1 (en) 1997-08-08 2011-06-15 Univ California TREATMENT OF BLADDER FIBROSIS WITH ANTIBODIES TO ALPHA-V BETA-6 INTEGRIN
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE19842415A1 (en) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmaceutical preparation for treating e.g. tumors, thrombosis or inflammation, contains cyclic pentapeptide integrin inhibitor and chemotherapeutic agent and/or angiogenesis inhibitor
HK1044159A1 (en) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 Humanized antibodies to gamma-interferon
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
CZ20011872A3 (en) 1999-09-29 2002-03-13 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamides for the treatment of integrin-mediated disorders
HK1047109A1 (en) 1999-10-15 2003-02-07 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
CA2397665A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
MXPA02007249A (en) 2000-02-03 2002-12-09 Eisai Co Ltd Integrin expression inhibitors.
US20020004042A1 (en) 2000-04-18 2002-01-10 Factor Phillip H. Gene therapy for pulmonary edema using adenovirus vectors encoding a beta2adrenergic receptor gene
AU2001269821A1 (en) 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
DE10041423A1 (en) 2000-08-23 2002-03-07 Merck Patent Gmbh biphenyl
US20020072500A1 (en) 2000-09-27 2002-06-13 Thomas Rogers Hydroxy acid integrin antagonists
DE60118025T2 (en) 2000-10-24 2006-11-23 Merck & Co., Inc. Dibenzoxazepine ALPHA-V integrin receptor ANTAGONIST
CA2433680A1 (en) 2000-12-28 2002-08-01 Gregory M Arndt Double-stranded rna-mediated gene suppression
WO2002081627A2 (en) 2001-04-04 2002-10-17 Allergan, Inc. Methods of screening and using inhibitors of angiogenesis
EP1389205B1 (en) 2001-04-09 2005-12-21 Ortho-McNeil Pharmaceutical Research Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
US20040019206A1 (en) 2001-09-27 2004-01-29 Peter Ruminiski Lactone integrin antagonists
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
AU2003259891A1 (en) 2002-08-16 2004-03-19 Janssen Pharmaceutica N.V. Piperidinyl compounds that selectively bind integrins
AU2005229015C1 (en) * 2004-04-02 2013-01-17 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
CN102083452A (en) * 2008-12-12 2011-06-01 犹他大学研究基金会 Compositions and methods for promoting vascular barrier function and treating pulmonary fibrosis
TWI552751B (en) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 Administration of 4-((1R,3S)-6-chloro-3-phenyl-dihydroindol-1-yl)-1,2,2-trimethyl-piperidin and its salts for the treatment of schizophrenia Methods
JP2016515120A (en) * 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Treatment and prevention of acute kidney injury using anti-alpha Vbeta5 antibody
EP3191519A1 (en) * 2014-09-12 2017-07-19 Biogen MA Inc. Humanized anti-alpha v beta 5 antibodies and uses thereof

Also Published As

Publication number Publication date
US20120328604A1 (en) 2012-12-27
WO2011011775A1 (en) 2011-01-27
KR20120052312A (en) 2012-05-23
AU2010275367B2 (en) 2015-09-03
CN102481347A (en) 2012-05-30
KR101752515B1 (en) 2017-06-29
JP5755647B2 (en) 2015-07-29
BR112012001463A2 (en) 2016-03-15
CA2767409C (en) 2018-10-30
US10087252B2 (en) 2018-10-02
EP2456460A1 (en) 2012-05-30
AU2010275367A1 (en) 2012-02-02
IL217406A (en) 2016-02-29
JP2013500269A (en) 2013-01-07
EP2456460A4 (en) 2013-02-20
CA2767409A1 (en) 2011-01-27
IL217406A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
IL261900A (en) Humanized antibodies against liv-1, compositions comprising the same and uses thereof
CY1122978T1 (en) ANTI-VLA-4 ANTIBODIES
TN2010000213A1 (en) Wise binding antibodies and epitopes
IL212099A0 (en) Cross-species specific psmaxcd3 bispecific single chain antibodies, compositions comprising the same and uses thereof
IL212100A0 (en) Cross-species-specific spcaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-irxcd3 or fapalphaxcd3 bispecific single chain antibodies, compositions comprising the same and uses thereof
PH12013500810B1 (en) Anti-il-23 antibodies
MX2010006396A (en) Bivalent, bispecific antibodies.
UA100874C2 (en) Bivalent bispecific antibodies
MX2010005682A (en) Bivalent, bispecific antibodies.
MX2010005888A (en) Bivalent, bispecific antibodies.
PH12014501108A1 (en) Anti-il-36r antibodies
IL216014A0 (en) Antibodies immunorective with heregulin-her3 complexes, compositions comprising the same and uses thereof
WO2013006490A3 (en) Antibodies that specifically bind to tim3
WO2012019024A3 (en) Her3-binding molecules and immunoconjugates thereof
EA201690310A1 (en) HUMAN CD27 ANTIBODIES AND THEIR APPLICATION
MX2014008102A (en) Dual variable domain immunoglobulins against receptors.
BR112013007229A2 (en) '' composition, mixing and process ''.
ZA201102081B (en) Engineered anti0il-13 antibodies,compositions,methods and uses
IN2012DN02046A (en)
EA201390575A1 (en) NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND THEIR IMMUNOCONJUGATES
IL212066A (en) Anti cxcr4 antibodies, compositions comprising them, processes for their production and selection and use thereof
PL2354161T3 (en) Anti-nr10 antibody, and use thereof
IL226023A0 (en) Anti-dr5 antibodies, compositions comprising the same and uses thereof
HUE037733T2 (en) Lyophilization methods, compositions, and kits
WO2011103490A3 (en) INTEGRIN αVβ8 NEUTRALIZING ANTIBODY